Eiger BioPharmaceuticals has said it will cut staffing numbers by 25% and refocus its R&D activities on metabolic diseases, after the FDA said it would need a new stud
Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh